Lyon Street Capital LLC bought a new stake in Stemline Therapeutics, Inc. (NASDAQ:STML) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 125,595 shares of the biopharmaceutical company’s stock, valued at approximately $1,155,000. Lyon Street Capital LLC owned about 0.54% of Stemline Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of STML. FMR LLC raised its position in shares of Stemline Therapeutics by 72.1% in the first quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock valued at $21,708,000 after buying an additional 1,063,457 shares during the last quarter. AXA acquired a new stake in shares of Stemline Therapeutics in the first quarter valued at about $3,712,000. Eventide Asset Management LLC raised its position in shares of Stemline Therapeutics by 27.6% in the first quarter. Eventide Asset Management LLC now owns 1,086,400 shares of the biopharmaceutical company’s stock valued at $9,289,000 after buying an additional 235,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Stemline Therapeutics by 32.9% in the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock valued at $7,055,000 after buying an additional 204,228 shares during the last quarter. Finally, Artal Group S.A. raised its position in shares of Stemline Therapeutics by 150.0% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $2,300,000 after buying an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 48.42% of the company’s stock.

Shares of Stemline Therapeutics, Inc. (NASDAQ STML) traded down 1.059% during midday trading on Friday, hitting $11.675. 70,682 shares of the company were exchanged. The company has a 50-day moving average price of $9.82 and a 200-day moving average price of $8.93. Stemline Therapeutics, Inc. has a 52-week low of $5.50 and a 52-week high of $14.60. The stock’s market capitalization is $273.84 million.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.18). Stemline Therapeutics had a negative net margin of 4,176.84% and a negative return on equity of 67.35%. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts forecast that Stemline Therapeutics, Inc. will post ($2.56) EPS for the current year.

A number of equities research analysts recently issued reports on STML shares. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Stemline Therapeutics in a report on Tuesday, September 12th. ValuEngine lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Finally, Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, June 14th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $32.60.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/10/06/125595-shares-in-stemline-therapeutics-inc-stml-purchased-by-lyon-street-capital-llc.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.